Clinical significance of tumor location for ureteroscopic tumor grading in upper tract urothelial carcinoma.


Journal

Journal of endourology
ISSN: 1557-900X
Titre abrégé: J Endourol
Pays: United States
ID NLM: 8807503

Informations de publication

Date de publication:
12 Sep 2024
Historique:
medline: 12 9 2024
pubmed: 12 9 2024
entrez: 12 9 2024
Statut: aheadofprint

Résumé

Although previous literature shows tumor location as a prognostic factor in upper tract urothelial carcinoma (UTUC), there remains uninvestigated regarding the impact of tumor location on grade concordance and discrepancies between ureteroscopic (URS) biopsy and final radical nephroureterectomy(RNU) pathology. In this international study, we retrospectively reviewed the records of 1,498 patients with UTUC who underwent diagnostic URS with concomitant biopsy followed by RNU between 2005 and 2020. Tumor location was divided into four sections: the calyceal-pelvic system, proximal ureter, middle ureter, and distal ureter. Patients with multifocal tumors were excluded from the study. We performed multiple comparison tests and logistic regression analyses. Overall, 1,154 patients were included; 54.4% of those with low-grade URS biopsies were upgraded on RNU. In the multiple comparison tests, middle ureter tumors exhibited the highest probability of upgrading, meanwhile pelvicalyceal tumors exhibited the lowest probability of upgrading (73.7% vs 48.5%, p=0.007). Downgrading was comparable across all tumor locations. On multivariable analyses, middle ureteral location was significantly associated with a low probability of grade concordance (OR 0.59; 95%CI, 0.35-1.00; p =0.049) and an increased risk of upgrading (OR 2.80; 95%CI, 1.20-6.52; p =0.017). The discordance did not vary regardless of caliceal location, including the lower calyx. Middle ureteral tumors diagnosed to be low-grade had a high probability to be undergraded. Our data can inform providers and their patients regarding the likelihood of undergrading according to tumor location, facilitating patient counselling and shared decision making regarding the choice of kidney sparing vs RNU.

Sections du résumé

BACKGROUND BACKGROUND
Although previous literature shows tumor location as a prognostic factor in upper tract urothelial carcinoma (UTUC), there remains uninvestigated regarding the impact of tumor location on grade concordance and discrepancies between ureteroscopic (URS) biopsy and final radical nephroureterectomy(RNU) pathology.
METHODS METHODS
In this international study, we retrospectively reviewed the records of 1,498 patients with UTUC who underwent diagnostic URS with concomitant biopsy followed by RNU between 2005 and 2020. Tumor location was divided into four sections: the calyceal-pelvic system, proximal ureter, middle ureter, and distal ureter. Patients with multifocal tumors were excluded from the study. We performed multiple comparison tests and logistic regression analyses.
RESULTS RESULTS
Overall, 1,154 patients were included; 54.4% of those with low-grade URS biopsies were upgraded on RNU. In the multiple comparison tests, middle ureter tumors exhibited the highest probability of upgrading, meanwhile pelvicalyceal tumors exhibited the lowest probability of upgrading (73.7% vs 48.5%, p=0.007). Downgrading was comparable across all tumor locations. On multivariable analyses, middle ureteral location was significantly associated with a low probability of grade concordance (OR 0.59; 95%CI, 0.35-1.00; p =0.049) and an increased risk of upgrading (OR 2.80; 95%CI, 1.20-6.52; p =0.017). The discordance did not vary regardless of caliceal location, including the lower calyx.
CONCLUSIONS CONCLUSIONS
Middle ureteral tumors diagnosed to be low-grade had a high probability to be undergraded. Our data can inform providers and their patients regarding the likelihood of undergrading according to tumor location, facilitating patient counselling and shared decision making regarding the choice of kidney sparing vs RNU.

Identifiants

pubmed: 39264866
doi: 10.1089/end.2024.0335
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Auteurs

Satoshi Katayama (S)

Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Urology, Shikata-cho, Okayama, Okayama, Japan, 7008558.
Medical University of Vienna, Urology, Wien, Austria, 1090; skatayama18@gmail.com.

Benjamin Pradere (B)

CHU Tours, Department of urology, 2 boulevard tonnellé, Tours, France, 37000; benjaminpradere@gmail.com.

Nico C Grossmann (NC)

Medical University of Vienna, Urology, Währinger Gürtel 18-20, Zurich, Austria, 8091.
University of Zurich, Urology, Frauenklinikstrasse 10, Zurich, Switzerland, 8006; nico.grossmann@gmail.com.

Aaron M Potretzke (AM)

Mayo Clinic, Urology, 200 1st St. SW, Rochester, Minnesota, United States, 55905; potretzke.aaron@mayo.edu.

Stephen J Boorjian (SJ)

Mayo Clinic, Urology, Rochester, Minnesota, United States; boorjian.stephen@mayo.edu.

Alireza Ghoreifi (A)

University of Southern California, Urology, 1441Eastlake Ave, Suite 7416, Los Angeles, California, United States, 90089; aghoreifi@gmail.com.

Siamak Daneshmand (S)

USC, Institute of Urology, 1441 Eastlake Ave, Suite 7416, Los Angeles, California, United States, 90024.
California, United States; daneshma@med.usc.edu.

Hooman Djaladat (H)

University of Southern California, Los Angeles, United States; djaladat@med.usc.edu.

John Sfakianos (J)

Icahn School of Medicine at Mount Sinai, Urology, 1425 madison ave L6-58, New York, New York, United States, 10029; john.sfakianos@mountsinai.org.

Andrea Mari (A)

Department of Urology, University of Florence, Careggi Hospital, Florence, Italy., Urology, Largo Brambilla 3, Firenze, Italy, 50100.
University of Florence, Careggi Hospital, Florence, Italy.; andreamari08@gmail.com.

Zine-Eddine Khene (ZE)

Hospital Pontchaillou, CHU Rennes, Department of Urology, Rennes, France; khene.zineddine@gmail.com.

David D'Andrea (D)

Medical University of Vienna, Wien, Austria; david.dandrea@meduniwien.ac.at.

Nozomi Hayakawa (N)

St. Marianna University, School of Medicine, Department of Urology, Kawasaki, Japan; hoffnungen0921@gmail.com.

Kazutoshi Fujita (K)

Kindai University Faculty of Medicine Hospital, Department of Urology, Osakasayama, Osaka, Japan; kfujita@med.kindai.ac.jp.

Axel Heidenreich (A)

University of Cologne, Faculty of Medicine and University Hospital Cologne, Department of Urology, Cologne, Germany, Cologne, Germany; axel.heidenreich@uk-koeln.de.

Jay D Raman (JD)

University of Texas - Southwestern Medical Center, Urology, 5323 Harry Hines Blvd., J8-106, Dallas, Texas, United States, 75390.
University of Texas - Southwestern Medical Center, Urology, United States; jraman@hmc.psu.edu.

Mathieu Roumiguie (M)

CHU Toulouse, Department of urology, Toulouse, France; roumiguie_mathieu@yahoo.fr.

Firas Abdollah (F)

Henry Ford Health System, Vattikuti Urology Institute, Center for Outcomes Research Analytics and Evaluation, 2799 West Grand Boulevard, Detroit, Michigan, United States, 48202; firas.abdollah@gmail.com.

Alberto Breda (A)

Fundacio Puigvert, Urology , Barcelona, Cataluña, Spain; albbred@gmail.com.

Matteo Fontana (M)

IRCCS Fondazione Ca' Granda - Ospedale Maggiore Policlinico, Urology, Via della Commenda 15, Milan, Italy, 20100; teo.fontana@me.com.

Morgan Roupret (M)

Pitié-Salpétrière Hospital, Academic Urology, 47-83 Boulevard de l'Hôpital, Paris, France, 75013.
France; mroupret@gmail.com.

Vitaly Margulis (V)

UT Southwestern Medical, Urology, 5339 harry hines blvd, Dallas, Texas, United States, 75390; vitaly.margulis@utsouthwestern.edu.

Pierre I Karakiewicz (PI)

University of Montreal Health Center, Cancer Prognostics and Health Outcomes Unit, Montreal, Quebec, Canada.
University of Montreal Health Center, Department of Urology, Montreal, Quebec, Canada; pierrekarakiewicz@gmail.com.

Motoo Araki (M)

Okayama University, Urology, 2-5-1 Shikata-cho, Okayama, Japan, 700-8558.
University of Oklahoma, Urology, 920 Stanton L Young Blvd WP3150, Oklahoma City, Oklahoma, United States, 73120; motoosh@md.okayama-u.ac.jp.

Yasutomo Nasu (Y)

okayama University, Urology, 2-5-1 Shikata, Okayama, Okayama, Japan, 700-8558; ynasu@md.okayama-u.ac.jp.

Shahrokh F Shariat (SF)

Medical University of Vienna, Wien, Wien, Austria; shahrokh.shariat@meduniwien.ac.at.

Classifications MeSH